[go: up one dir, main page]

BRPI0418695A - uso terapêutico de anticorpos anti-cs1 - Google Patents

uso terapêutico de anticorpos anti-cs1

Info

Publication number
BRPI0418695A
BRPI0418695A BRPI0418695-8A BRPI0418695A BRPI0418695A BR PI0418695 A BRPI0418695 A BR PI0418695A BR PI0418695 A BRPI0418695 A BR PI0418695A BR PI0418695 A BRPI0418695 A BR PI0418695A
Authority
BR
Brazil
Prior art keywords
antibodies
antagonists
subject
therapeutic use
present
Prior art date
Application number
BRPI0418695-8A
Other languages
English (en)
Inventor
Marna Williams
J Yun Tso
Nicholas F Landolfi
David B Powers
Robert B Dubridge
Debbie Law
Gao Liu
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Publication of BRPI0418695A publication Critical patent/BRPI0418695A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO TERAPêUTICO DE ANTICORPOS ANTI-CS1. A presente invenção é direcionada a antagonistas de CS1 que se ligam e neutralizam pelo menos uma atividade biologica de CS1. A invenção também inclui uma composição farmacêutica compreendendo tais anticorpos ou fragmentos de ligação de antígeno desses. A presente invenção também fornece um método de prevenir ou tratar estados de doença, incluíndo distúrbios autoimunes e câncer, em um individuo que necessite disso, compreendendo administrar ao dito indivíduo uma qualidade eficaz de tais antagonistas.
BRPI0418695-8A 2004-03-29 2004-11-08 uso terapêutico de anticorpos anti-cs1 BRPI0418695A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55762204P 2004-03-29 2004-03-29
US55762104P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
PCT/US2004/037430 WO2005102387A2 (en) 2004-03-29 2004-11-08 Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
BRPI0418695A true BRPI0418695A (pt) 2007-06-12

Family

ID=35197500

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418695-8A BRPI0418695A (pt) 2004-03-29 2004-11-08 uso terapêutico de anticorpos anti-cs1

Country Status (13)

Country Link
US (6) US7709610B2 (pt)
EP (2) EP2301576B1 (pt)
KR (1) KR101146775B1 (pt)
CN (1) CN1960750B (pt)
AT (1) ATE482722T1 (pt)
AU (2) AU2004318675B2 (pt)
BR (1) BRPI0418695A (pt)
CA (1) CA2561065A1 (pt)
DE (1) DE602004029399D1 (pt)
IL (1) IL178121A (pt)
MX (1) MXPA06011241A (pt)
PL (1) PL2301576T3 (pt)
WO (1) WO2005102387A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005085288A2 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research Natural igm antibodies and inhibitors thereof
US20100136684A1 (en) * 2004-03-01 2010-06-03 Carroll Michael C Natural IgM Antibodies
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
CA2660102C (en) * 2006-08-07 2017-02-21 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
EP2641601B8 (en) * 2006-08-07 2016-09-21 AbbVie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib
WO2008019379A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
RS58233B1 (sr) 2006-11-02 2019-03-29 Genentech Inc Humanizovana anti-faktor d antitela i njihove upotrebe
US20100152136A1 (en) * 2006-12-08 2010-06-17 Shaughnessy Jr John D TP53 Gene expression and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
EP2316031B1 (en) 2008-08-19 2016-09-14 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment
US8603477B2 (en) * 2008-10-31 2013-12-10 Abbvie Biotherapeutics Inc. Use of anti-CS1 antibodies for treatment of rare lymphomas
ES2629630T3 (es) 2008-12-04 2017-08-11 Curna, Inc. Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
ES2583691T3 (es) 2009-06-26 2016-09-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
DK2519542T3 (en) * 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
WO2012162277A1 (en) * 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
EP2890715B1 (en) * 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
NO2760138T3 (pt) 2012-10-01 2018-08-04
CA2905940A1 (en) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized, anti-n2 antibodies
EP3729958B1 (en) * 2013-03-15 2023-05-03 Mayo Foundation for Medical Education and Research Identification and monitoring of monoclonal immunoglobulins by molecular mass
JP6574754B2 (ja) * 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
AU2014259675B2 (en) 2013-05-03 2019-05-02 Ohio State Innovation Foundation CS1-specific chimeric antigen receptor engineered immune effector cells
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
SG10201800889SA (en) 2013-08-01 2018-03-28 Univ Catholique Louvain Anti-garp protein and uses thereof
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
KR20160067846A (ko) * 2013-09-05 2016-06-14 듀크 유니버시티 Nav1.7 항체 및 그의 사용 방법
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
US10494433B2 (en) 2013-11-06 2019-12-03 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
MX2016008098A (es) * 2013-12-20 2017-01-11 Hoffmann La Roche Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
CA2955984A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
EP3175242A4 (en) 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
US10011657B2 (en) 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
MX2017007097A (es) * 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
US10973914B2 (en) 2015-02-20 2021-04-13 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
PL3313528T3 (pl) 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka
US11209439B2 (en) 2015-09-24 2021-12-28 Mayo Foundation For Medical Education And Research Identification of immunoglobulin free light chains by mass spectrometry
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP4043492A1 (en) 2016-03-01 2022-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
US10955420B2 (en) 2016-09-07 2021-03-23 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
AU2017366739B2 (en) 2016-12-02 2023-11-23 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
EP3351271A1 (en) * 2017-01-23 2018-07-25 TheraPharm GmbH Radioimmunoconjugate for use in treating bone marrow associated diseases
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
EP3681528B1 (en) 2017-09-13 2025-07-23 Mayo Foundation for Medical Education and Research Identification and monitoring of apoptosis inhibitor of macrophage
WO2019055632A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN CHAINS J
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
CA3103610A1 (en) 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
US11951131B2 (en) 2018-07-03 2024-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SLAMF7 chimeric antigen receptors
CA3119467A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
JP7520848B2 (ja) 2018-12-28 2024-07-23 スパークス・セラピューティクス・インコーポレイテッド 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
AU2020298572A1 (en) 2019-07-02 2021-11-18 Fred Hutchinson Cancer Center Recombinant Ad35 vectors and related gene therapy improvements
US20220390455A1 (en) 2019-11-05 2022-12-08 Bristol-Myers Squibb Company M-protein assays and uses thereof
CN115243724B (zh) 2020-02-19 2025-10-21 纳米医疗有限公司 可用于治疗癌症的经调配和/或共调配的含有TFGβ拮抗剂前药的脂质体组合物和其方法
WO2022206941A1 (zh) * 2021-04-02 2022-10-06 克莱格医学有限公司 Cs1工程化细胞及其组合物
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO2001016318A2 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1996039518A1 (en) 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
JP2001522239A (ja) * 1997-03-21 2001-11-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ８７個のヒト分泌タンパク質
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6020599A (en) 1998-08-25 2000-03-14 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1159284A4 (en) 1999-02-10 2003-10-29 Human Genome Sciences Inc 33 HUMAN SECRETARY PROTEINS
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3750000A (en) 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030215450A1 (en) 2000-05-26 2003-11-20 Blake Simon M Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
WO2002022660A2 (en) * 2000-09-11 2002-03-21 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1381622A2 (en) 2001-03-21 2004-01-21 Human Genome Sciences, Inc. Human secreted proteins
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003018621A2 (en) 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
KR102028770B1 (ko) 2011-09-15 2019-10-04 컨버전트 인포메이션 테크놀로지스 게엠베하 로봇 프로그램의 자동 생성을 위한 시스템 및 방법
US9505153B2 (en) 2012-02-13 2016-11-29 Radius Engineering, Inc. Reusable cartridge for injection molding

Also Published As

Publication number Publication date
WO2005102387A3 (en) 2006-03-09
US8349330B2 (en) 2013-01-08
US8088898B2 (en) 2012-01-03
WO2005102387A2 (en) 2005-11-03
MXPA06011241A (es) 2007-01-16
US8444980B2 (en) 2013-05-21
US20060024296A1 (en) 2006-02-02
DE602004029399D1 (pt) 2010-11-11
CN1960750A (zh) 2007-05-09
US20120064067A1 (en) 2012-03-15
AU2004318675A1 (en) 2005-11-03
US20120064069A1 (en) 2012-03-15
CN1960750B (zh) 2011-06-29
KR101146775B1 (ko) 2012-05-21
AU2011200999B2 (en) 2012-05-31
KR20070011412A (ko) 2007-01-24
US20120064068A1 (en) 2012-03-15
PL2301576T3 (pl) 2013-02-28
US20090246852A1 (en) 2009-10-01
AU2004318675B2 (en) 2011-06-16
EP2301576B1 (en) 2012-09-19
IL178121A0 (en) 2008-03-20
EP2301576A1 (en) 2011-03-30
IL178121A (en) 2016-12-29
US8461306B2 (en) 2013-06-11
ATE482722T1 (de) 2010-10-15
US7709610B2 (en) 2010-05-04
AU2011200999A1 (en) 2011-03-31
EP1729803B1 (en) 2010-09-29
US20120070440A1 (en) 2012-03-22
CA2561065A1 (en) 2005-11-03
EP1729803A4 (en) 2007-08-08
EP1729803A2 (en) 2006-12-13
US8436146B2 (en) 2013-05-07

Similar Documents

Publication Publication Date Title
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
DK2853272T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
BRPI0622073A8 (pt) Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
MA28418B1 (fr) Anticorps liant un recepteur de l&#39;interleucine 4
TW200513468A (en) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2
WO2003097082A3 (en) Treatment of crohn&#39;s disease or psoriasis using anti-inteferon gamma antibodies
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FACET BIOTECH CORPORATION (US)

Free format text: TRANSFERIDO DE: PDL BIOPHARMA, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ABBOTT BIOTHERAPEUTICS CORP. (US)

B25D Requested change of name of applicant approved

Owner name: ABBVIE BIOTHERAPEUTICS INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL